Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortIL-12/23 antibody for psoriasis and inflammatory bowel disease.Biologic injection for arthritis, IBD and psoriasis.
Body systemJoints & ImmunityJoints & Immunity
Drug classInterleukin inhibitorsTNF inhibitors
SupplyPrescription onlyWHO essential medicinePrescription only
Main usesPlaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitisRheumatoid and psoriatic arthritis, Ankylosing spondylitis, Crohn's disease and ulcerative colitis, Psoriasis, Hidradenitis suppurativa
How it worksBlocks inflammation signals IL-12 and IL-23.Mops up a key inflammation signal.
Starts workingWeeks—
Half-lifeAbout 3 weeksAbout 2 weeks
Typical adult dose45–90 mg subcutaneously at weeks 0 and 4 then every 12 weeks (psoriasis); IV induction in IBD.40 mg under the skin every other week (some conditions start higher or go weekly).
FormsSubcutaneous injection, IV infusion (induction)Pre-filled pen, Pre-filled syringe
Common side effectsUpper respiratory infections, Headache, Tiredness, Injection site rednessInjection-site reactions, Upper respiratory infections, Headache
Serious side effectsSerious infections, Allergic reactions, Reversible leukoencephalopathy (rare)Serious infections including TB reactivation, Lymphoma (rare), Demyelination, Heart failure worsening
Don't take ifActive serious infection; Active TB—
AlcoholUsually no problem in moderation. No specific interaction.—
PregnancyUse with cautionLimited data; may be continued when benefit outweighs risk.Use with cautionOften continued into pregnancy for IBD; baby's live vaccines may be delayed.
BreastfeedingUse with cautionLimited data.—
In use since—2002
Brand namesUnited States: Stelara, WezlanaUnited Kingdom: Stelara, WezenlaIndia: Stelara, Ustekinumab biosimilarsUnited States: Humira, Hadlima, Hyrimoz, YuflymaUnited Kingdom: Humira, Amgevita, Imraldi, YuflymaIndia: Exemptia, Adfrar
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H—
ATC codeL04AC05L04AB04

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker